Centrient Pharmaceuticals

Centrient Pharmaceuticals, a Pharmaceutical Preparation Manufacturing company based in the Netherlands, reported its latest emissions in 2025, with a total of approximately 601,812,000 kg CO2e. This includes about 101,489,000 kg CO2e from Scope 1 emissions, around 148,005,000 kg CO2e from Scope 2 (market-based), and approximately 352,318,000 kg CO2e from Scope 3 emissions.

In 2024, the company's total emissions were approximately 697,019,000 kg CO2e, comprising roughly 142,884,000 kg CO2e for Scope 1, about 118,053,000 kg CO2e for Scope 2 (market-based), and around 436,083,000 kg CO2e for Scope 3. For 2023, total emissions were approximately 732,956,000 kg CO2e, with Scope 1 at about 143,291,000 kg CO2e, Scope 2 (market-based) at around 141,432,000 kg CO2e, and Scope 3 at approximately 448,232,000 kg CO2e. In 2022, Centrient Pharmaceuticals reported total emissions of approximately 641,257,000 kg CO2e, including roughly 136,734,000 kg CO2e for Scope 1, about 145,740,000 kg CO2e for Scope 2 (market-based), and around 358,783,000 kg CO2e for Scope 3.

Centrient Pharmaceuticals has set ambitious climate commitments. The company has a Science Based Target initiative (SBTi) approved target to reduce absolute Scope 1 and 2 GHG emissions by 46.2% by 2031 from a 2022 base year. This target is classified as consistent with reductions required to keep warming to 1.5°C. Additionally, Centrient Pharmaceuticals is committed to reducing absolute Scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities by 27.5% within the same timeframe (2022-2031). These SBTi targets were set by Centrient Pharmaceuticals itself. The company also aims for a 35% reduction in carbon emission intensity by 2025 and 50% by 2030, using 2021 as a baseline year.